FindTrial
Sign In

MVA-BN-Brachyury

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI), University of Utah, Bavarian Nordic

Conditions

Advanced Solid TumorMetastatic Castration-resistant Prostate CancerNon-metastatic Castration-resistant Prostate CancerProstate AdenocarcinomaProstate CancerProstate NeoplasmSolid Metastatic TumorSolid Tumor

Phase 1

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
CompletedNCT03493945
National Cancer Institute (NCI)Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer +3
Start: 2018-05-01End: 2024-10-08Updated: 2025-09-30
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
CompletedNCT04134312
Bavarian NordicSolid Metastatic Tumor
Start: 2020-01-08End: 2021-04-06Updated: 2021-07-14

Phase 2

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
WithdrawnNCT04020094
University of UtahProstate Adenocarcinoma
Start: 2019-11-20End: 2021-04-09Updated: 2021-09-22

Related Papers

Abstract A027: Peripheral Immune Dynamics and Biomarkers of Clinical Response in Patients with Castration-Resistant Prostate Cancer Treated with Combination Immunotherapy
Cancer Immunology Research2026-02-18
582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer
Regular and Young Investigator Award Abstracts2021-11-012 citations
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
Journal for ImmunoTherapy of Cancer2021-09-0136 citations
A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.
Journal of Clinical Oncology2021-05-20
A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax).
Journal of Clinical Oncology2020-02-194 citations
Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.
Journal of Clinical Oncology2019-05-20
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Journal for ImmunoTherapy of Cancer2018-09-1858 citations